{
    "2018-01-09": [
        [
            {
                "time": "2018-01-02",
                "original_text": "AbbVie Rapidly Advancing Its 2018 Solid Tumor Portfolio",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Advancing",
                        "Solid Tumor",
                        "Portfolio"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "5 Ways Gilead Sciences Plans to Return to Growth",
                "features": {
                    "keywords": [
                        "Gilead",
                        "Sciences",
                        "Return",
                        "Growth"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Notable Tuesday Option Activity: MCK, ABBV, BIIB",
                "features": {
                    "keywords": [
                        "Option",
                        "Activity",
                        "MCK",
                        "ABBV",
                        "BIIB"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "AbbVie's Upadacitinib Gains Breakthrough Therapy Designation",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Upadacitinib",
                        "Breakthrough",
                        "Therapy",
                        "Designation"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Is AbbVie Stock Still A Strong Buy?",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Stock",
                        "Strong",
                        "Buy"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "AbbVie’s Venclexta for Chronic Lymphocytic Leukemia",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Venclexta",
                        "Chronic",
                        "Lymphocytic",
                        "Leukemia"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "AbbVie Expects Peak Sales of $7 Billion for Imbruvica",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Peak",
                        "Sales",
                        "Imbruvica"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "4 Best Marijuana Stocks to Play the Green Rush",
                "features": {
                    "keywords": [
                        "Marijuana",
                        "Stocks",
                        "Green",
                        "Rush"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "cannabis"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "AbbVie's JAK1 Inhibitor Granted FDA's Breakthrough Therapy",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "JAK1",
                        "Inhibitor",
                        "FDA",
                        "Breakthrough",
                        "Therapy"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Ex-Dividend Reminder: Patterson Companies, AbbVie and Abbott Laboratories",
                "features": {
                    "keywords": [
                        "Ex-Dividend",
                        "Patterson",
                        "Companies",
                        "AbbVie",
                        "Abbott",
                        "Laboratories"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Why AbbVie Is Focused on Expanding Risankizumab’s Label for Multiple Immunology Indications",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Risankizumab",
                        "Label",
                        "Immunology",
                        "Indications"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "See what the IHS Markit Score report has to say about AbbVie Inc.",
                "features": {
                    "keywords": [
                        "IHS",
                        "Markit",
                        "Score",
                        "report",
                        "AbbVie"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Cramer's lightning round: Mercadolibre is even better tha...",
                "features": {
                    "keywords": [
                        "Cramer",
                        "lightning",
                        "round",
                        "Mercadolibre"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "technology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}